National CineMedia Inc. (NCMI) Q4 2024 Earnings Call Transcript: Insights from the Company’s Financial Performance Discussion

National CineMedia, Inc. (NASDAQ: NCMI ) Q4 2024 Earnings Conference Call On March 6, 2025, at 5:00 PM ET, National CineMedia, Incorporated (NCMI) held its Fourth Quarter 2024 Earnings Conference Call. The participants included Chan Park, VP of Finance, Tom Lesinski, CEO, and Ronnie Ng, CFO. The call was moderated by an operator. Two analysts,…

Read More

Levi and Korsinsky Investigation Reminder for Shareholders of Company X: Important Information to Know

Levi & Korsinsky Investigates Semtech Corporation: Net Sales of CopperEdge Products Expected to Fall Below Estimates In a recent development, Levi & Korsinsky, a securities litigation firm based in New York, NY, has initiated an investigation into Semtech Corporation (NASDAQ: SMTC) regarding potential securities law violations. The investigation comes in response to Semtech’s announcement on…

Read More

Newlake Capital Partners, Inc. (NLCP) Q4 2024 Earnings Call Transcript: Insights from Management

NewLake Capital Partners, Inc. (NLCP) Q4 2024 Earnings Conference Call On March 6, 2025, at 11:00 AM ET, NewLake Capital Partners, Inc. (NLCP) held its Q4 2024 earnings conference call. The call was hosted by Valter Pinto, Managing Director at KCSA Strategic Communications, with Independent Chairman Gordon DuGan, President, CEO & Director Anthony Coniglio, SVP…

Read More

Starbucks Serves Up a Huge Surprise: A Delightful Discussion on Their Record-Breaking Day

Starbucks Faces Challenges: Labor Inflation, Competition, and High Input Costs Starbucks Corporation, the world’s largest coffeehouse chain, has been grappling with a series of headwinds that have negatively impacted its financial performance and stock price. These challenges include labor inflation, intense competition, and high input costs. Labor Inflation Rising labor costs have been a significant…

Read More

Ginkgo Bioworks Q4 2024 Earnings Call Transcript: Insights from the DNA-Driven Organism Design Company

Ginkgo Bioworks Holdings, Inc. Q4 2024 Earnings Conference Call: Insights and Impacts On February 25, 2025, Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) held its Q4 2024 earnings conference call. The call was led by Joseph Fridman, Director of Communications and Corporate Affairs, with participation from Jason Kelly, Founder, CEO & Director, Mark Dmytruk, CFO, and…

Read More

Regulus Therapeutics Unveils Q4-2024 Financial Results and Recent Updates: A New Chapter in Gene Therapy

Positive Interim Results in Phase 1b Clinical Trial of Farabursen (RGLS8429) for Autosomal Dominant Polycystic Kidney Disease Regulus Therapeutics, a biopharmaceutical company specializing in microRNA-targeted medicines, recently reported encouraging findings from the interim analysis of the fourth cohort in the Phase 1b multiple-ascending dose (MAD) clinical trial of their investigational drug, farabursen (RGLS8429), for the…

Read More